Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

Nicola Personeni, Alain Hendlisz, Julien Gallez, Maria Gomez Galdon, Denis Larsimont, Jean Luc Van Laethem, Nathalie Nagy, Martine Barette, Marianne Paesmans, Fatima Cardoso, Harry Bleiberg

Research output: Contribution to journalArticlepeer-review

Abstract

Despite staining positive for the epidermal growth factor receptor (EGFR), a significant number of EGFR-expressing colorectal cancers are resistant to cetuximab, a chimeric monoclonal antibody directed against EGFR. Activation of EGFR through the autophosphorylation of its tyrosine residues stimulates different signaling downstream pathways and may reflect the level of receptor utilization by the tumor. This study investigated activated/phosphorylated EGFR (pEGFR) in 23 patients with EGFR-positive metastatic colorectal cancer refractory to irinotecan and treated with cetuximab, alone or in combination with irinotecan. Seven patients received cetuximab, and 16 patients received cetuximab plus irinotecan. Among the 23 patients, six (26%) had a partial response, 10 (44%) had stable disease, and seven (30%) had progressive disease. Median duration of disease control (partial response + stable disease) was 6 months. Nineteen out of 20 EGFR-positive tumors (95%) stained positive for pEGFR and had a median pEGFR immunohistochemical score of 5. Disease control rates differed between patients with a pEGFR immunohistochemical score <7 (7/7, 100%) and less than 7 (7/13, 53.8%), showing a trend toward higher disease control in patients with high levels of pEGFR (<7) who were treated with cetuximab with or without irinotecan (P = .05).

Original languageEnglish
JournalSeminars in Oncology
Volume32
Issue numberSUPPL. 9
DOIs
Publication statusPublished - Dec 2005

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this